Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYZOMIT is a multi-ingredient nutritional supplement and branded generic product developed by Zaiva Lifesciences. It is formulated as an oral tablet containing a combination of acetyl-L-carnitine (100 mg), coenzyme Q10 (10 mg), and omega-3 fatty acids. Acetyl-L-carnitine facilitates the transport of long-chain fatty acids into the mitochondria for beta-oxidation and energy production. Coenzyme Q10 serves as a vital electron carrier in the mitochondrial respiratory chain, aiding in ATP synthesis and providing antioxidant protection against oxidative stress. Omega-3 fatty acids are included to support cardiovascular health and maintain lipid balance. The product is marketed in India for general health maintenance, energy metabolism support, and cardiovascular wellness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CYZOMIT.